Sarepta Therapeutics (SRPT) News Today

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw mixed investor sentiment today. A safety clarification regarding Elevidys provided some relief, but a flurry of class-action reminders and regulatory setbacks weighed on the stock, while analysts remain divided on the long-term outlook.

• Positive Sentiment: Sarepta confirmed that two Elevidys patient deaths recently posted on an FDA database were deemed unrelated to its gene-therapy treatment, easing safety concerns. StockWatch: Sarepta Says Deaths of Two Elevidys Patients Posted on FDA Database Unrelated to Treatment
• Neutral Sentiment: Sarepta was reported to have a short-interest ratio of 0.0 days as of August 11, though the underlying data appeared inconclusive.
• Neutral Sentiment: Despite an 85% drop in 2025, some Wall Street firms still see up to 179% upside for Sarepta shares based on longer-term valuation metrics. Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
• Negative Sentiment: The EMA recommended refusing marketing authorization for Elevidys, prompting another decline in SRPT shares. Sarepta Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization
• Negative Sentiment: Levi & Korsinsky reminded shareholders of the August 25, 2025 deadline to apply as lead plaintiff in a proposed securities-fraud class action covering June 2023–June 2025. Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline
• Negative Sentiment: Faruqi & Faruqi launched an investigation into potential claims on behalf of Sarepta investors and encouraged those with losses to get in touch. SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Investigates Claims
• Negative Sentiment: Investors were reminded of the August 25 deadline to join a class action lawsuit against Sarepta. August 25, 2025 Deadline Approaching: Join Class Action Against Sarepta Therapeutics
• Negative Sentiment: Bragar Eagel & Squire reminded investors that a class action has been filed against Sarepta and noted the lead-plaintiff application deadline. SAREPTA (SRPT) LAWSUIT ALERT: Bragar Eagel & Squire
• Negative Sentiment: Levi & Korsinsky also issued a notice about a pending securities-fraud class action and urged investors to contact the firm before August 25. Sarepta Therapeutics Inc. Securities Fraud Class Action Lawsuit Pending
• Negative Sentiment: Pomerantz LLP alerted investors to a class action suit and upcoming filing deadlines related to their Sarepta holdings. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors of Class Action Lawsuit
• Negative Sentiment: The Gross Law Firm issued a lawsuit alert and reminded shareholders of the final deadline to participate. SRPT LAWSUIT ALERT: The Gross Law Firm Notifies Investors of a Class Action Lawsuit
• Negative Sentiment: DJS Law Group reminded shareholders they have the right to lead the securities lawsuit against Sarepta before the final deadline. SRPT Shareholders Have the Right to Lead the Sarepta Securities Lawsuit
• Negative Sentiment: Bernstein Liebhard announced a securities-fraud class action has been filed against Sarepta. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces Securities Fraud Class Action
• Negative Sentiment: BFA Law issued a court notice advising investors they may have been affected by fraud and to contact the firm before August 25 if they suffered losses. SRPT COURT NOTICE: Contact BFA Law Before August 25
• Negative Sentiment: TipRanks highlighted the ongoing class action lawsuit filed by Levi & Korsinsky, underscoring continued legal pressure. SRPT Lawsuit Alert Class Action Lawsuit Against Sarepta
• Negative Sentiment: Barron's noted that shares of Sarepta, along with other major tech and biotech names, were down in early trading. These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More